Literature DB >> 26131866

Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Brazilian Portuguese.

Juliana Catucci Boza1, Roopal V Kundu2, Amanda Fabbrin1, Roberta Horn1, Natalia Giongo1, Tania Ferreira Cestari1.   

Abstract

BACKGROUND: Vitiligo, although asymptomatic, highly compromises patients' quality of life (QoL). Therefore, an adequate evaluation of QoL is essential.
OBJECTIVES: Translation, cultural adaptation and validation of VitiQol (Vitiligo-specific health-related quality of life instrument) into Brazilian Portuguese.
METHODS: The study was conducted in two stages; the first stage was the translation and cultural/linguistic adaptation of the instrument; the second stage was the instrument's validation.
RESULTS: The translated VitiQol showed high internal consistency (Cronbach alpha = 0.944) and high test-retest reliability and intraclass correlation coefficient=0.95 (CI 95% 0.86 - 0.98), p<0.001. There was no statistically significant difference between the means of the first completion of the VitiQoL questionnaire and the retest, p = 0.661. There was a significant correlation between VitiQoL and DLQI (r = 0.776, p <0.001) and also between VitiQoL-PB and subjects' assessment of the severity of their disease (r = 0.702, p <0.001).
CONCLUSIONS: The impact of vitiligo on the QoL of Brazilian patients can be assessed by a specific questionnaire.

Entities:  

Mesh:

Year:  2015        PMID: 26131866      PMCID: PMC4516093          DOI: 10.1590/abd1806-4841.20153684

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


INTRODUCTION

Vitiligo is an acquired pigmentary disorder, characterized by achromatic spots due to a loss of melanocytes. Its prevalence ranges between 0.5% and 1% worldwide. Gujarat, India, is considered to be the place with the highest prevalence of vitiligo: approximately 8.8%.[1] The average age of onset is 22 years in the United States and India, 24 years in Brazil and 25 years in England, and half of the patients develop the disease before 20 years of age.[1],[2],[3] Adults and children of both genders are equally affected, but some studies indicate a slight preponderance of cases among females, possibly because women seek medical care more often than men due to the secondary psychosocial consequences.[3],[4],[5],[6] There is no predilection for skin type or race.[1] There are genetic factors involved in its etiopathogenesis, and the relative risk of vitiligo in first-degree relatives is estimated as seven to 10 times greater than in the general population.[3],[7] Other aspects involved include autoimmunity, intrinsic defects of melanocytes and T-cells, and oxidative stress.[8]-[11] Many dermatological diseases are characterized by compromising patients' physical and relational well-being. For this reason, the assessment of quality of life (QoL) is of fundamental importance.[12],[13] Vitiligo, although asymptomatic, highly compromises QoL. It affects patients' lives in many ways, being sometimes psychologically devastating. The condition compromises self-esteem, body image and social life. Individuals with vitiligo suffer social discrimination and stigmatization, which result in significant changes in their lifestyles: from the choice of clothing, use of sunscreen and cosmetic camouflage of the lesions to the avoidance of social events or outdoor activities.[14]-[17] Recently, a specific questionnaire for vitiligo has been developed and validated in the English language: the Vitiligo-specific health-related quality of life instrument (VitiQoL).[17] To this date, there were no instruments in Brazilian Portuguese to assess the QoL in vitiligo. The VitiQoL is a questionnaire of 15 items, with item scores from 0 (never) to 6 (all the time). It yields a total score from 0 to 90. Moreover, it presents a personal assessment of the severity of vitiligo, using a scale ranging from 0 (no skin involvement) to 6 (worst case), which corresponds to the 16th question of the VitiQoL questionnaire. The questionnaire shows to be a promising clinical and epidemiological study instrument, and a powerful marker of outcome.[17] The aim of this study was to perform the translation, cross-cultural adaptation and validation of the VitiQoL into Brazilian Portuguese (VitiQoL-PB).

METHODS

The author of the VitiQoL questionnaire authorized its translation, cross-cultural adaptation and validation. The study was conducted in two stages: the first stage was the translation and cultural/linguistic adaptation of the instrument; the second stage was the instrument's validation. This is an observational study. Subjects were divided into two groups: cross-sectional and follow-up (retest). Subjects were selected from a Dermatological Outpatient Clinic from Hospital de Clínicas de Porto Alegre. In this study, we used convenience sampling of consecutive cases. Inclusion criteria were: older than 18 years of age; able to read and understand Brazilian Portuguese; diagnosis of vitiligo confirmed by a dermatologist. Exclusion criteria were: presence of chronic, non-dermatological disease or other concomitant dermatological disease. In the first stage (translation and cross-cultural adaptation), two independent translators performed the literal translation of the VitiQoL instrument from English into Portuguese. This version was later reviewed by a bilingual group, composed of health professionals. Next, 10 subjects with vitiligo were asked to answer the questionnaire and make suggestions for its clarity and understanding. After repeat review by the same bilingual group, this new version of the questionnaire was translated into English and sent to the author of the original questionnaire for approval. This stage took place from January to June 2013. Based on the original study and the WHO recommendations for the development of quality of life questionnaires, a specific questionnaire on demographic data, the VitiQoL questionnaire and a generic instrument for dermatological diseases previously validated for Portuguese, the DLQI (Dermatology Life Quality Index), were administered to 74 subjects. In addition, subjects made a personal assessment of their severity of vitiligo, using a scale ranging from 0 (no skin involvement) to 6 (most severe cases), which corresponded to the 16th question of the VitiQoL-PB questionnaire. For test-retest reliability, the sample was calculated based on the studies reliability graph, using a reliability coefficient (Cronbach's coefficient) of 0.80 and a confidence interval of 0.05. Statistical analysis was performed using SPSS (SPSS Inc. Chicago, II, version 18.0 for Windows). The reliability of the instrument was demonstrated through the analysis of internal consistency using Cronbach's coefficient of reliability. Test-retest reliability was assessed by intraclass correlation coefficient (ICC) and Student t test for paired samples. The PB-VitiQoL and DLQI were compared using the Pearson correlation coefficient. General data were analyzed using descriptive statistics (mean and standard deviation for quantitative variables with symmetric distribution; median and interquartile range for variables with asymmetric distribution; and frequencies and percentages for categorical variables). The study project was approved by the Research Ethics Committee and all subjects signed an informed consent.

RESULTS

The questionnaire was completed by 74 subjects. For analysis of reproducibility (test-retest reliability), two to four weeks after the first interview, a subgroup of subjects, corresponding to 20% of the sample, completed the VitiQol-PB questionnaire again. Subjects' demographic and clinical characteristics are described in table 1. The translated VitiQol showed high internal consistency (Cronbach alpha = 0.944) and high test-retest reliability, with an intraclass correlation coefficient of 0.95 (CI 95% 0.86 - 0.98), p<0.001. There was no statistically significant difference between the means of the first completion of the VitiQoL questionnaire and the retest, p = 0.661 (Graph 1)|. The 95% interval of agreement between the test and retest was -25.46 to 22.71.
TABLE 1

Clinical and demographic data

 Mean
(standard deviation)
Age44.70 (17.107)
Age of onset31 (median)
Duration of the disease11 (median)
 N(%)
Gender  
Male24(32.4)
Female50(67.6)
Skin type  
II12(16.2)
III31(41.9)
IV26(35.1)
V5(6.8)
Educational level  
Incomplete primary education21(28.4)
Complete primary education3(4.1)
Incomplete secondary education13(17.6)
Complete secondary education12(16.2)
Incomplete higher education12(16.2)
Complete higher education13(17.6)
Marital status  
Married27(36.4)
Divorced/ Separated12(16.2)
Widowed6(8.3)
Single29(39.1)
Income  
up to 500.003(4.1)
500.00-1,000.0020(27)
1,000.00-3,000.0033(44.6)
>3,000.0016(21.6)
Was unable to report2(2.7)
GRAPH 1

Clinical and demographic data Bland and Altman’s graph showing agreement between test and retest scores. The solid line shows the difference between the means of the test and the retest; the dotted line shows the 95% limits of agreement (mean difference ± 1.96SD)

Clinical and demographic data Clinical and demographic data Bland and Altman’s graph showing agreement between test and retest scores. The solid line shows the difference between the means of the test and the retest; the dotted line shows the 95% limits of agreement (mean difference ± 1.96SD) The single item that most contributed to the total score of VitiQoL-PB was related to the frustration about the skin condition (question 2). Other items that significantly contributed to the final scores were: feeling bothered by the appearance of the skin (question 1), worry about what other people think (question 5), fear of criticism (question 6), embarrassment or inhibition because of the skin (question 7), social or leisure activities (question 9), emotional well-being (question 10). In general, we found that all items contributed to the final score (Table 2).
TABLE 2

Correlation between items and between the items with the final score

ItemCorrelation between itemsCorrelation between the items and the final score
1- Bother0.27-0.840.83
2 - Frustration0.28-0.850.85
3 - Difficulty showing affection0.25-0.670.69
4- Daily activities0.29-0.750.77
5 - Worry about what other people think0.17-0.840.81
6 - Fear of criticism0.17-0.840.82
7 - Embarrassment or inhibition0.35-0.850.83
8 - Type of clothing0.25-0.680.72
9 - Social and leisure activities0.30-0.750.81
10- Emotional well-being0.21-0.750.83
11- Physical health as a whole0.24-0.710.70
12 - Care with personal appearance0.24-0.590.66
13 - Sun protection care0.12-0.350.41
14- Making new friends0.12-0.670.75
15- Disease progression0.24-0.590.62
Correlation between items and between the items with the final score The average VitiQoL-PB score was 40.04+27.32; while the median DLQI was 3 (interquartile range P25 = 1 and P75 = 7). The average patient assessment score for severity of illness was 3.64 + 1.87 (Figure 1).
FIGURE 1

VitiQoL PB

Reproduced with permission of the authors ALL RIGHTS RESERVED © Lilly E, Kundu RV 2012. Any unauthorized use or reproduction of this document is strictly prohibited.

VitiQoL PB Reproduced with permission of the authors ALL RIGHTS RESERVED © Lilly E, Kundu RV 2012. Any unauthorized use or reproduction of this document is strictly prohibited. There was a significant correlation between VitiQoL and DLQI (r = 0.776, p <0.001) and also between VitiQoL-PB and subjects' assessment of the severity of their disease (r = 0.702, p <0.001). We also found a good correlation between the total DLQI and subjects' assessment of the severity of their disease (r = 0.673, p <0.001) (Graph 2).
GRAPH 2

Correlation between VitiQoL-PB, DLQI and question 16 of VitiQoL (self-reported severity of vitiligo)

Correlation between VitiQoL-PB, DLQI and question 16 of VitiQoL (self-reported severity of vitiligo)

DISCUSSION

The development and validation of dermatology-specific QoL questionnaires is recent.[18],[19] For the evaluation of a specific dermatosis, there is a tendency to combine two questionnaires: one generic questionnaire and another disease-specific dermatologic questionnaire, comparing both scores.[20] Disease-specific instruments are already available for several chronic dermatoses, such as atopic dermatitis, acne and melasma.[21]->[23] The absence of a vitiligo-specific questionnaire for the assessment of QoL led to the use of the general dermatology questionnaires, such as DLQI and Skindex-16. However, they do not seem to be sensitive enough for the assessment of an asymptomatic disease such as vitiligo.[24] For conditions like acne and psoriasis, it has been shown that specific questionnaires better reflect QoL.[25],[26] In addition, they make it possible to correlate clinical and demographic aspects of a specific population with QoL.[27],[28],[29] The VitiQoL-PB Cronbach's alpha coefficient was similar to the coefficient of the original questionnaire (original VitiQoL Cronbach's alpha = 0.935), which demonstrates the reliability of the instrument. Additionally, it showed a strong correlation with both the subjects' assessment of disease severity and the DLQI. In the original VitiQoL, one of the limitations highlighted by the authors was the fact that no assessment of test-retest reliability had been carried out. In our study, 16 subjects (21% of the sample) completed the VitiQoL-PB a second time, confirming the high test-retest reliability with an intraclass correlation coefficient (ICC) of 0.95 (95% CI, 0.86 to 0.98). The intraclass correlation coefficient ensures the reproducibility of the questionnaire, and ICC values ≥ 0.75 are considered excellent.

CONCLUSION

There are little data on the quality of life of patients with vitiligo in Brazil. Most studies have been conducted in children, by using the Children's Dermatology Life Quality Index.[30],[31] Studies conducted with adults generally use the DLQI and the SF-36 (Medical Outcomes Study 36-item Short-Form Health Survey).[32],[33] Moving forward, the impact of vitiligo on the quality of life of Brazilian patients can be assessed using a disease-specific questionnaire, which will contribute to a more complete and reliable evaluation of these patients. Vitiligo is a chronic disease and, although it is asymptomatic, it highly compromises patients' quality of life (QoL). The translation, cross-cultural adaptation and validation of the VitiQoL-PB will not only assist in treatment evaluation and in the comparison of results of studies conducted in different regions of Brazil, but also allow the correlation with international data
  32 in total

Review 1.  The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review.

Authors:  John De Korte; Femke M C Mombers; Mirjam A G Sprangers; Jan D Bos
Journal:  Arch Dermatol       Date:  2002-09

Review 2.  Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up.

Authors:  Ali Alikhan; Lesley M Felsten; Meaghan Daly; Vesna Petronic-Rosic
Journal:  J Am Acad Dermatol       Date:  2011-09       Impact factor: 11.527

Review 3.  Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials.

Authors:  V Eleftheriadou; K S Thomas; M E Whitton; J M Batchelor; J C Ravenscroft
Journal:  Br J Dermatol       Date:  2012-10       Impact factor: 9.302

4.  Responsiveness of the Acne-Specific Quality of Life Questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials.

Authors:  S E Fehnel; L D McLeod; J Brandman; D I Arbit; C J McLaughlin-Miley; J H Coombs; A R Martin; C J Girman
Journal:  Qual Life Res       Date:  2002-12       Impact factor: 4.147

5.  Circulating autoantibodies and autoimmune comorbidities in vitiligo patients: a multicenter Italian study.

Authors:  Vito Ingordo; Simone Cazzaniga; Beatrice Raone; Maria Donata Digiuseppe; Maria Letizia Musumeci; Dario Fai; Michele Pellegrino; Enrico Pezzarossa; Vito Di Lernia; Vincenzo Claudio Battarra; Riccardo Sirna; Annalisa Patrizi; Luigi Naldi
Journal:  Dermatology       Date:  2014-03-05       Impact factor: 5.366

6.  Assessment of the quality of life of pediatric patients with the major chronic childhood skin diseases.

Authors:  Ana Paula Dornelles da Silva Manzoni; Rita Langie Pereira; Roberta Zaffari Townsend; Magda Blessmann Weber; Aline Rodrigues da Silva Nagatomi; Tania Ferreira Cestari
Journal:  An Bras Dermatol       Date:  2012 May-Jun       Impact factor: 1.896

7.  Role of oxidative stress and autoimmunity in onset and progression of vitiligo.

Authors:  Naresh C Laddha; Mitesh Dwivedi; Mohmmad Shoab Mansuri; Mala Singh; Amina R Gani; Asmita P Yeola; Vipul N Panchal; Fazal Khan; Darshana J Dave; Ananddeep Patel; Shajil E Madhavan; Richa Gupta; Zarna Marfatia; Yogesh S Marfatia; Rasheedunnisa Begum
Journal:  Exp Dermatol       Date:  2014-05       Impact factor: 3.960

Review 8.  Vitiligo--part 1.

Authors:  Roberto Gomes Tarlé; Liliane Machado do Nascimento; Marcelo Távora Mira; Caio Cesar Silva de Castro
Journal:  An Bras Dermatol       Date:  2014 May-Jun       Impact factor: 1.896

9.  Acne-specific quality of life questionnaire (Acne-QoL): translation, cultural adaptation and validation into Brazilian-Portuguese language.

Authors:  Cristhine de Souza Leão Kamamoto; Karime Marques Hassun; Ediléia Bagatin; Jane Tomimori
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

10.  Quality of life profile and correlated factors in chronic leg ulcer patients in the mid-west of São Paulo State, Brazil.

Authors:  Patrick Alexander Wachholz; Paula Yoshiko Masuda; Dejair Caitano Nascimento; Cecilia Midori Higashi Taira; Norma Gondim Cleto
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

View more
  6 in total

1.  Vitiligo-specific instrument on quality of life - Brazilian Portuguese version.

Authors:  Juliana Catucci Boza; Natália Piccinini Giongo; Tania Ferreira Cestari
Journal:  An Bras Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.896

2.  Evaluation of treatment response to autologous transplantation of noncultured melanocyte/keratinocyte cell suspension in patients with stable vitiligo.

Authors:  Mariana Gontijo Ramos; Daniel Gontijo Ramos; Camila Gontijo Ramos
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

3.  Clinico-Epidemiological Profile and Treatment Pattern of Vitiligo in Selected Dermatological Clinics of Mekelle City, Northern Ethiopia.

Authors:  Afewerki Gebremeskel Tsadik; Goitom Fitsum Legesse; Desilu Mahari Desta; Brhane Teklebrhan Assefa; Hailekiros Gebretsadik Kidanemariam; Meles Tekie Gidey
Journal:  Dermatol Res Pract       Date:  2020-05-30

4.  Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Polish.

Authors:  Tomasz Iwanowski; Piotr Szlązak; Monika Zabłotna; Berenika Olszewska; Małgorzata Sokołowska-Wojdyło
Journal:  Postepy Dermatol Alergol       Date:  2021-09-17       Impact factor: 1.837

5.  Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL).

Authors:  Kosar Hedayat; Mojgan Karbakhsh; Maryam Ghiasi; Azadeh Goodarzi; Yousef Fakour; Zahra Akbari; Afsaneh Ghayoumi; Narges Ghandi
Journal:  Health Qual Life Outcomes       Date:  2016-06-07       Impact factor: 3.186

6.  Public Knowledge and Attitudes towards Vitiligo: A Survey in Mekelle City, Northern Ethiopia.

Authors:  Afewerki Gebremeskel Tsadik; Mezgebe Zeru Teklemedhin; Tesfay Mehari Atey; Meles Tekie Gidey; Desilu Mahari Desta
Journal:  Dermatol Res Pract       Date:  2020-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.